CervoMed Inc. (CRVO)Healthcare | Biotechnology | Boston, United States | NasdaqCM
2.60 USD
-0.04
(-1.515%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.56 -0.04 (-0.040%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:23 a.m. EDT
The immediate outlook is severely compromised by a massive gap between the current price of $2.62 and the analyst consensus target mean of $15.80, which suggests significant upside potential only if the company can execute a turnaround. However, the fundamental reality is stark: the business is burning cash aggressively with operating margins of -94%, negative free cash flow, and a trailing P/E that indicates no earnings to speak of. The balance sheet shows a current ratio of 8.57, which initially looks like a fortress, but this liquidity is likely propped up by the recent $10 million registered direct offering mentioned in the news, rather than organic cash generation. The stock has suffered a catastrophic long-term decline, dropping nearly 99.9% over the last nine years, with only one year of recovery followed by another steep drop. While insiders buying shares recently offers a glimmer of hope regarding management confidence, the lack of any dividend history and the persistent losses suggest this is a speculative gamble on a future drug approval rather than an investment in a functioning business. The statistical forecast models also lean slightly negative for the near term, reinforcing the view that the market is currently pricing in continued distress. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.112230 |
| AutoARIMA | 0.162523 |
| AutoETS | 0.162727 |
| MSTL | 0.180847 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.218 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.035 |
| Market Cap | 39,309,648 |
| Forward P/E | -1.76 |
| Beta | -4.31 |
| Website | https://www.cervomed.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.73861384 |
| Address1 | 20 Park Plaza |
| Address2 | Suite 424 |
| All Time High | 2,902,500.0 |
| All Time Low | 1.8 |
| Ask | 3.26 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 330,590 |
| Average Daily Volume3 Month | 5,719,732 |
| Average Volume | 5,719,732 |
| Average Volume10Days | 330,590 |
| Beta | -4.31 |
| Bid | 1.88 |
| Bid Size | 2 |
| Book Value | 1.697 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.6 |
| Current Ratio | 8.572 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.6699 |
| Day Low | 2.55 |
| Display Name | CervoMed |
| Dividend Date | 1,544,745,600 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 43.38 |
| Enterprise Value | 14,371,478 |
| Eps Current Year | -2.202 |
| Eps Forward | -1.475 |
| Eps Trailing Twelve Months | -3.15 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0334 |
| Fifty Day Average Change | -0.43340015 |
| Fifty Day Average Change Percent | -0.14287603 |
| Fifty Two Week Change Percent | -73.86138 |
| Fifty Two Week High | 10.89 |
| Fifty Two Week High Change | -8.290001 |
| Fifty Two Week High Change Percent | -0.7612489 |
| Fifty Two Week Low | 2.13 |
| Fifty Two Week Low Change | 0.4699998 |
| Fifty Two Week Low Change Percent | 0.22065717 |
| Fifty Two Week Range | 2.13 - 10.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,211,549,400,000 |
| Float Shares | 9,604,406 |
| Forward Eps | -1.475 |
| Forward P E | -1.7627118 |
| Free Cashflow | -16,289,585 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 15 |
| Fullday Change | -0.0400002 |
| Fullday Change Percent | -1.51516 |
| Fullday Price | 2.56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -21,504,800 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.26433 |
| Held Percent Institutions | 0.22286 |
| Implied Shares Outstanding | 15,119,096 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,692,230,400 |
| Last Split Factor | 2:3 |
| Long Business Summary | CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts. |
| Long Name | CervoMed Inc. |
| Market | us_market |
| Market Cap | 39,309,648 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_280597237 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -30,349,744 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 40,062,580 |
| Number Of Analyst Opinions | 5 |
| Open | 2.64 |
| Operating Cashflow | -27,977,672 |
| Operating Margins | -94.06961 |
| Payout Ratio | 0.0 |
| Phone | 617 744 4400 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -1.5384601 |
| Post Market Price | 2.56 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 2.64 |
| Price Eps Current Year | -1.1807448 |
| Price Hint | 4 |
| Price To Book | 1.5321155 |
| Price To Sales Trailing12 Months | 118.65452 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.225 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0400002 |
| Regular Market Change Percent | -1.51516 |
| Regular Market Day High | 2.6699 |
| Regular Market Day Low | 2.55 |
| Regular Market Day Range | 2.55 - 2.6699 |
| Regular Market Open | 2.64 |
| Regular Market Previous Close | 2.64 |
| Regular Market Price | 2.6 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 263,833 |
| Return On Assets | -0.60799 |
| Return On Equity | -1.07623 |
| Revenue Per Share | 0.035 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 15,119,096 |
| Shares Percent Shares Out | 0.0637 |
| Shares Short | 962,576 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 827,455 |
| Short Name | CervoMed Inc. |
| Short Percent Of Float | 0.0787 |
| Short Ratio | 2.1 |
| Source Interval | 15 |
| State | MA |
| Symbol | CRVO |
| Target High Price | 25.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 15.4 |
| Target Median Price | 15.0 |
| Total Cash | 24,938,172 |
| Total Cash Per Share | 1.649 |
| Total Debt | 0 |
| Total Revenue | 331,295 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.7881 |
| Two Hundred Day Average Change | -2.1880999 |
| Two Hundred Day Average Change Percent | -0.4569871 |
| Type Disp | Equity |
| Volume | 263,833 |
| Website | https://www.cervomed.com |
| Zip | 2,116 |